Plasma Cell Myeloma Refractory clinical trials

Explore recruiting plasma cell myeloma refractory clinical trials.

Recruiting plasma cell myeloma refractory studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Plasma Cell Myeloma Refractory trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

Spain, Italy, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase 1/2 trial evaluating isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma (RRMM)

Norway, France, Italy, Germany, Portugal, Greece

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol Phase 1/2 trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) - control arm

France, Portugal, Norway, Italy, Germany, Greece

Phase I and Phase II (Integrated)- Other EU CTIS Study details

"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

Poland, Spain, Czechia, France, Italy, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/2 trial evaluating isatuximab in combination with belantamab mafodotin and dexamethasone in relapsed or refractory multiple myeloma (RRMM)

Italy, Greece, Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Spain, Norway, Germany, Greece, France, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Plasma Cell Myeloma Refractory trials by city

Plasma Cell Myeloma Refractory in Toronto Plasma Cell Myeloma Refractory in Vancouver Plasma Cell Myeloma Refractory in Montreal Plasma Cell Myeloma Refractory in Calgary Plasma Cell Myeloma Refractory in Edmonton Plasma Cell Myeloma Refractory in Ottawa Plasma Cell Myeloma Refractory in Winnipeg Plasma Cell Myeloma Refractory in Quebec City Plasma Cell Myeloma Refractory in Hamilton Plasma Cell Myeloma Refractory in Kitchener Plasma Cell Myeloma Refractory in London Plasma Cell Myeloma Refractory in Halifax Plasma Cell Myeloma Refractory in New York Plasma Cell Myeloma Refractory in Los Angeles Plasma Cell Myeloma Refractory in Chicago Plasma Cell Myeloma Refractory in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease